Last reviewed · How we verify
Telmisartan, Ramipril
This combination blocks angiotensin II signaling through two complementary pathways: telmisartan blocks the angiotensin II type 1 receptor, while ramipril inhibits ACE to prevent angiotensin II formation.
This combination blocks angiotensin II signaling through two complementary pathways: telmisartan blocks the angiotensin II type 1 receptor, while ramipril inhibits ACE to prevent angiotensin II formation. Used for Hypertension, Cardiovascular risk reduction in hypertensive patients.
At a glance
| Generic name | Telmisartan, Ramipril |
|---|---|
| Also known as | cardace, cardiopri, tazloc |
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Drug class | Angiotensin II receptor blocker + ACE inhibitor combination |
| Target | AT1 receptor (telmisartan); Angiotensin-converting enzyme (ramipril) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Telmisartan is an angiotensin II receptor blocker (ARB) that directly antagonizes AT1 receptors, preventing vasoconstriction and aldosterone release. Ramipril is an ACE inhibitor that reduces angiotensin II production by blocking the conversion of angiotensin I. Together, they provide dual renin-angiotensin-aldosterone system (RAAS) inhibition for enhanced blood pressure reduction and cardiovascular protection.
Approved indications
- Hypertension
- Cardiovascular risk reduction in hypertensive patients
Common side effects
- Dizziness
- Cough
- Hyperkalemia
- Hypotension
- Fatigue
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN (PHASE4)
- Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study (PHASE4)
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: